281 related articles for article (PubMed ID: 34816617)
21. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Wilson WH; Jung SH; Porcu P; Hurd D; Johnson J; Martin SE; Czuczman M; Lai R; Said J; Chadburn A; Jones D; Dunleavy K; Canellos G; Zelenetz AD; Cheson BD; Hsi ED;
Haematologica; 2012 May; 97(5):758-65. PubMed ID: 22133772
[TBL] [Abstract][Full Text] [Related]
22. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
[TBL] [Abstract][Full Text] [Related]
24. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
25. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients.
Ahn HK; Kim SJ; Yun J; Yi JH; Kim JH; Won YW; Kim K; Ko YH; Kim WS
Int J Hematol; 2010 Apr; 91(3):456-63. PubMed ID: 20198460
[TBL] [Abstract][Full Text] [Related]
26. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
[TBL] [Abstract][Full Text] [Related]
27. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
28. [Standard CHOP immuno-chemotherapy for primary mediastinal lymphomas].
Schneider T; Tóth E; Lovey J; Molnár Z; Deák B; Várady E; Csomor J; Matolcsy A; Lengyel Z; Petri K; Gaudi I; Rosta A
Orv Hetil; 2011 May; 152(19):735-42. PubMed ID: 21498163
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of clinical characteristics and
Liu Y; Jiang J; Liu L; Wang Z; Yu B; Xia Z; Zhang Q; Ji D; Liu X; Lv F; Hong X; Song S; Cao J
J Int Med Res; 2022 Jan; 50(1):3000605211063027. PubMed ID: 35001690
[TBL] [Abstract][Full Text] [Related]
30. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkısh oncology group study.
Acar R; Paydaş S; Yıldırım M; Kılıçarslan E; Sahın U; Dogan A; Guven DC; Ekıncı O; Tıglıoglu M; Erdogan I; Elıbol T; Kızıloz H; Aykan MB; Sayın S; Kaptan K; Soydan E; Gokmen A; Esen R; Barısta I; Albayrak M; Erturk I; Yıldız B; Keskın GY; Aylı M; Karadurmus N
J Cancer Res Ther; 2023 Apr; 19(Supplement):S138-S144. PubMed ID: 37147993
[TBL] [Abstract][Full Text] [Related]
31. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH
Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL.
Pinnix CC; Ng AK; Dabaja BS; Milgrom SA; Gunther JR; Fuller CD; Smith GL; Abou Yehia Z; Qiao W; Wogan CF; Akhtari M; Mawlawi O; Medeiros LJ; Chuang HH; Martin-Doyle W; Armand P; LaCasce AS; Oki Y; Fanale M; Westin J; Neelapu S; Nastoupil L
Blood Adv; 2018 Jun; 2(11):1334-1343. PubMed ID: 29895624
[TBL] [Abstract][Full Text] [Related]
33. Real-world efficacy of DA-EPOCH-R/HD-MTX regimen in CD5-positive diffuse large B cell lymphoma: a single-institute analysis.
Toyama K; Nakayama K; Terasaki S; Matsumura I; Kanaya S; Iino H; Noguchi H; Tahara K; Yoshida T; Saito A
J Clin Exp Hematop; 2023; 63(1):19-24. PubMed ID: 36990773
[TBL] [Abstract][Full Text] [Related]
34. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
Dunleavy K; Pittaluga S; Maeda LS; Advani R; Chen CC; Hessler J; Steinberg SM; Grant C; Wright G; Varma G; Staudt LM; Jaffe ES; Wilson WH
N Engl J Med; 2013 Apr; 368(15):1408-16. PubMed ID: 23574119
[TBL] [Abstract][Full Text] [Related]
35. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z; Dujmovic D; Jaksic O; Kinda SB; Gacina P; Perisa V; Prka Z; Dreta B; Galusic D; Holik H; Pejsa V; Aurer I
Eur J Haematol; 2023 Jun; 110(6):725-731. PubMed ID: 36941738
[TBL] [Abstract][Full Text] [Related]
36. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Ramos JC; Sparano JA; Rudek MA; Moore PC; Cesarman E; Reid EG; Henry D; Ratner L; Aboulafia D; Lee JY; Ambinder RF; Mitsuyasu R; Noy A
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):180-190.e2. PubMed ID: 29426719
[TBL] [Abstract][Full Text] [Related]
37. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Wilson WH; Dunleavy K; Pittaluga S; Hegde U; Grant N; Steinberg SM; Raffeld M; Gutierrez M; Chabner BA; Staudt L; Jaffe ES; Janik JE
J Clin Oncol; 2008 Jun; 26(16):2717-24. PubMed ID: 18378569
[TBL] [Abstract][Full Text] [Related]
39. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
Burke GAA; Minard-Colin V; Aupérin A; Alexander S; Pillon M; Delgado R; Zsíros J; Uyttebroeck A; Dartigues P; Miles RR; Kazanowska B; Chiang AK; Haouy S; Bollard CM; Csoka M; Wheatley K; Barkauskas DA; Adamson PC; Vassal G; Patte C; Gross TG
J Clin Oncol; 2021 Nov; 39(33):3716-3724. PubMed ID: 34570655
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma.
Park S; Jo JC; Do YR; Yang DH; Lim SN; Lee WS; Kim WS; Lee HS; Hong DS; Kim HJ; Shin HJ
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):149-156. PubMed ID: 30581162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
